320 related articles for article (PubMed ID: 33284114)
1. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.
Bandyopadhyay AS; Gast C; Rivera L; Sáez-Llorens X; Oberste MS; Weldon WC; Modlin J; Clemens R; Costa Clemens SA; Jimeno J; Rüttimann R
Lancet Infect Dis; 2021 Apr; 21(4):559-568. PubMed ID: 33284114
[TBL] [Abstract][Full Text] [Related]
2. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
[TBL] [Abstract][Full Text] [Related]
3. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R;
Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.
Sutter RW; Bahl S; Deshpande JM; Verma H; Ahmad M; Venugopal P; Rao JV; Agarkhedkar S; Lalwani SK; Kunwar A; Sethi R; Takane M; Mohanty L; Chatterjee A; John TJ; Jafari H; Aylward RB
Lancet; 2015 Dec; 386(10011):2413-21. PubMed ID: 26388534
[TBL] [Abstract][Full Text] [Related]
6. Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis.
Jaiswal N; Singh S; Agarwal A; Chauhan A; Thumburu KK; Kaur H; Singh M
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011780. PubMed ID: 31858595
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic.
Rivera Mejía L; Peña Méndez L; Bandyopadhyay AS; Gast C; Mazara S; Rodriguez K; Rosario N; Zhang Y; Mainou BA; Jimeno J; Aguirre G; Rüttimann R
Lancet Infect Dis; 2024 Mar; 24(3):275-284. PubMed ID: 38109921
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.
Snider CJ; Zaman K; Estivariz CF; Yunus M; Weldon WC; Wannemuehler KA; Oberste MS; Pallansch MA; Wassilak SG; Bari TIA; Anand A
Lancet; 2019 Jun; 393(10191):2624-2634. PubMed ID: 31104832
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.
Clarke E; Saidu Y; Adetifa JU; Adigweme I; Hydara MB; Bashorun AO; Moneke-Anyanwoke N; Umesi A; Roberts E; Cham PM; Okoye ME; Brown KE; Niedrig M; Chowdhury PR; Clemens R; Bandyopadhyay AS; Mueller J; Jeffries DJ; Kampmann B
Lancet Glob Health; 2016 Aug; 4(8):e534-47. PubMed ID: 27364568
[TBL] [Abstract][Full Text] [Related]
11. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.
Sáez-Llorens X; Clemens R; Leroux-Roels G; Jimeno J; Clemens SA; Weldon WC; Oberste MS; Molina N; Bandyopadhyay AS
Lancet Infect Dis; 2016 Mar; 16(3):321-30. PubMed ID: 26719058
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial.
Estívariz CF; Anand A; Gary HE; Rahman M; Islam J; Bari TI; Wassilak SG; Chu SY; Weldon WC; Pallansch MA; Heffelfinger JD; Luby SP; Zaman K
Lancet Infect Dis; 2015 Aug; 15(8):898-904. PubMed ID: 26093980
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
Sáez-Llorens X; Bandyopadhyay AS; Gast C; Leon T; DeAntonio R; Jimeno J; Caballero MI; Aguirre G; Oberste MS; Weldon WC; Konopka-Anstadt JL; Modlin J; Bachtiar NS; Fix A; Konz J; Clemens R; Costa Clemens SA; Rüttimann R
Lancet; 2021 Jan; 397(10268):27-38. PubMed ID: 33308427
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule.
Anand A; Molodecky NA; Pallansch MA; Sutter RW
Vaccine; 2017 May; 35(22):2993-2998. PubMed ID: 28434691
[TBL] [Abstract][Full Text] [Related]
16. Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America.
Lopez-Medina E; Melgar M; Gaensbauer JT; Bandyopadhyay AS; Borate BR; Weldon WC; Rüttimann R; Ward J; Clemens R; Asturias EJ
Vaccine; 2017 Jun; 35(28):3591-3597. PubMed ID: 28455172
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
De Coster I; Leroux-Roels I; Bandyopadhyay AS; Gast C; Withanage K; Steenackers K; De Smedt P; Aerssens A; Leroux-Roels G; Oberste MS; Konopka-Anstadt JL; Weldon WC; Fix A; Konz J; Wahid R; Modlin J; Clemens R; Costa Clemens SA; Bachtiar NS; Van Damme P
Lancet; 2021 Jan; 397(10268):39-50. PubMed ID: 33308429
[TBL] [Abstract][Full Text] [Related]
18. Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis.
Macklin GR; Grassly NC; Sutter RW; Mach O; Bandyopadhyay AS; Edmunds WJ; O'Reilly KM
Lancet Infect Dis; 2019 Oct; 19(10):1121-1128. PubMed ID: 31350192
[TBL] [Abstract][Full Text] [Related]
19. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.
Anand A; Zaman K; Estívariz CF; Yunus M; Gary HE; Weldon WC; Bari TI; Steven Oberste M; Wassilak SG; Luby SP; Heffelfinger JD; Pallansch MA
Vaccine; 2015 Nov; 33(48):6816-22. PubMed ID: 26476367
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.
Qiu J; Yang Y; Huang L; Wang L; Jiang Z; Gong J; Wang W; Wang H; Guo S; Li C; Wei S; Mo Z; Xia J
Hum Vaccin Immunother; 2017 Jun; 13(6):1-10. PubMed ID: 28362135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]